Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical firm focused on innovative treatments for spinal muscular atrophy and other serious conditions, announced granting inducement equity awards to two new employees. These awards consist of stock options for 25,714 shares and restricted stock units for 19,286 shares of common stock, all subject to the terms of the 2022 Inducement Equity Plan and associated agreements.
The Plan, adopted by the board of directors, allows for equity grants to individuals joining Scholar Rock to induce employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price matching the April 8, 2024 closing stock price and vesting terms tied to the employees’ tenure.
Scholar Rock focuses on developing therapies targeting protein growth factors, with a pipeline addressing neuromuscular diseases, cardiometabolic disorders, and cancer. Notably, the company has shown clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy, demonstrating its commitment to pioneering novel therapeutic approaches.
